Sierra Oncology Announces Presentation at LifeSci Partners Precision Oncology Day
Sierra Oncology, Inc. (SRRA) will have its President and CEO, Stephen Dilly, present at the LifeSci Partners Precision Oncology Day on February 17, 2021. The company focuses on targeted therapies for rare cancers and is advancing its development of momelotinib, aimed at changing the cancer treatment paradigm. A replay of the presentation will be accessible post-event on the company's website. The press release also includes forward-looking statements regarding the company's clinical development activities and potential challenges, including the risk of insufficient cash resources and impacts from COVID-19.
- Presentation by CEO Stephen Dilly at a significant oncology event.
- Focus on targeted therapies for rare forms of cancer indicates a niche market opportunity.
- Potential development of momelotinib could transform treatment approaches.
- Risks of insufficient cash resources to fund operations.
- COVID-19 impacts could disrupt clinical development timelines.
- Uncertainty regarding the safety and efficacy of momelotinib.
SAN MATEO, Calif., Feb. 12, 2021 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced that President and Chief Executive Officer Stephen Dilly, MBBS, PhD, will present an overview of the company at the LifeSci Partners Precision Oncology Day taking place Wednesday, February 17, 2021.
A replay of the presentation will be available following the conference on the Investors section of Sierra's corporate website in the Events & Webcast tab.
About Sierra Oncology
Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer. We harness our deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology. Our team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Together we are transforming promise into patient impact.
For more information, visit www.SierraOncology.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Sierra Oncology's expectations from current data, anticipated clinical development activities, expected timing and success of enrollment of MOMENTUM and potential benefits of momelotinib. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, including, among others, the risk that Sierra Oncology's cash resources may be insufficient to fund its current operating plans and it may be unable to raise additional capital when needed, the risk that disruptions and impacts of COVID-19 will be significant and lengthy, Sierra Oncology may be unable to successfully develop and commercialize momelotinib, momelotinib may not demonstrate safety and efficacy or otherwise produce positive results, Sierra Oncology may experience delays in the clinical development of momelotinib, Sierra Oncology may be unable to acquire additional assets to build a pipeline of additional product candidates, Sierra Oncology's third-party manufacturers may cause its supply of materials to become limited or interrupted or fail to be of satisfactory quantity or quality, Sierra Oncology may be unable to obtain and enforce intellectual property protection for its technologies and momelotinib and the other factors described under the heading "Risk Factors" set forth in Sierra Oncology's filings with the Securities and Exchange Commission from time to time. Sierra Oncology undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.
View original content:http://www.prnewswire.com/news-releases/sierra-oncology-announces-presentation-at-lifesci-partners-precision-oncology-day-301227345.html
SOURCE Sierra Oncology
FAQ
What is the date of Sierra Oncology's presentation at the Precision Oncology Day?
Who is presenting for Sierra Oncology at the conference?
What is Sierra Oncology focusing on in its research?
What risks does Sierra Oncology mention in its press release?
Where can I find more information after the presentation?
